Based on these results, the U.S. Food and Drug Administration and the European Medicines Agency have approved 177Lu-Oxodotreotide for the treatment of SSTR2-positive gastroenteropancreatic neuroendocrine tumors in patients aged 12 years and older. Here, SSTR2 is linked to neuroendocrine neoplasm.